Annalisa Jenkins is a proven biopharmaceutical executive and global healthcare leader with a distinguished track record of advancing innovation from bench to bedside. She formerly served as CEO of Dimension Therapeutics and as Head of Global Drug Development and Medical Affairs at Merck Serono, following senior leadership roles at Bristol Myers Squibb.
Over the course of her career, Annalisa has contributed to the development and commercialisation of more than 30 therapeutics across multiple modalities and disease areas, demonstrating deep clinical and commercial expertise. Her operational leadership is matched by a global perspective, with current board and advisory roles spanning the United States, United Kingdom, and Asia. These include the British Heart Foundation, Cancer Research Horizons at Cancer Research UK, and Genomics England. She previously served on the U.S. FDA’s Science Board.
